Cenegermin-bkbj

Brand names: Oxervate · Active ingredient: Cenegermin

In short: OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

Forms & strengthsOphthalmic solution: cenegermin-bkbj 0.002% (20 mcg/mL) as a clear, colorless solution in a multiple dose vial.
LabelDompé farmaceutici S.p.A.
Label updatedNov 13, 2026

What is Cenegermin-bkbj used for?

OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.

Cenegermin-bkbj dosage

Contact lenses should be removed before applying OXERVATE and may be reinserted 15 minutes after administration.

If a dose is missed, treatment should be continued as normal, at the next scheduled administration.

If more than one topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.

Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks.

Remove the weekly carton(s) containing OXERVATE vials from the insulated pack and store it for up to 14 days in a refrigerator (no later than 5 hours from when you receive the medicine from your pharmacy). OXERVATE is stored in a freezer at the pharmacy. If treatment is started immediately after receiving the weekly carton, wait until the first vial is thawed (this could take up to 30 minutes when kept at room temperature up to 77°F (25°C)). Do not shake the vial.

Follow Steps 1 to 19 each day you use OXERVATE:

Take an individual vial of OXERVATE from the refrigerator in the morning and prepare it in the following way:

Step 1. Wash your hands.

Step 2. If you wear contact lenses, take them out before using OXERVATE.

Step 3. Remove the plastic flip-off cap from the vial.

Step 4. Verify that the vial adapter is seated correctly within the blister cavity. If the adapter is displaced, gently press it back into place by pressing the blister lid while the blister remains sealed. Peel-off the back of the vial adapter blister pack. If the vial adapter falls out of its packaging, do not use it and replace it with a new one.

Step 5. Without removing the vial adapter from its blister pack, connect it to the vial by firmly pushing it down until it snaps into place over the neck of the vial. The spike of the vial adapter should pierce through the vial’s rubber stopper. After the vial adapter has been connected correctly, do not remove it from the vial.

Note: After the vial adapter is connected to the vial, OXERVATE can be stored in the refrigerator between 36°F to 46°F (2°C to 8°C) for up to 12 hours.

If needed, the OXERVATE with the connected vial adapter may be stored at room temperature up to 77°F (25°C).

Step 6. Remove and throw away the packaging of the vial adapter.

The multi-dose vial of OXERVATE is now ready for use (1 drop in the affected eye every 2 hours six times a day).

To withdraw and give each dose of OXERVATE, follow the Steps 7 to 19:

Step 7. Take a single sterile disinfectant wipe and gently clean the surface of the valve on the connector part of the vial adapter.

After cleaning, wait for about 1 minute to allow the valve to dry.

Step 8. Remove a pipette from its protective packaging.

Step 9. …

How to take Cenegermin-bkbj — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Handling the Vials and the Delivery System

Advise patients that OXERVATE should be administered using the vial adapters, pipettes, and sterile disinfectant wipes provided in the Delivery System Kit and according to the instructions . One individual pipette should be used per application.

Use with Contact Lenses

Advise patients that contact lenses should be removed before applying OXERVATE and to wait 15 minutes after instillation of the dose before reinserting the contact lenses into the eyes .

Use with other topical products

Advise the patient to administer the eye drops at least 15 minutes apart, if more than one topical ophthalmic product is being used to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.

Delayed or Missed Dose

If a dose is missed, treatment should be continued as normal, at the next scheduled administration. …

Warnings & precautions

Do not take this medicine if: None.

Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration.

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs.

Cenegermin-bkbj side effects

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

In two clinical trials of patients with neurotrophic keratitis, a total of 101 patients received cenegermin-bkbj eye drops at 20 mcg/mL at a frequency of 6 times daily in the affected eye(s) for a duration of 8 weeks. The mean age of the population was 61 to 65 years of age (18 to 95). The majority of the treated patients were female (61%). The most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs.

Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache.

The following adverse reactions have been identified during postapproval use of OXERVATE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Eye disorders

: eye irritation, blepharitis (including eyelid margin crusting and eyelid edema) and corneal neovascularization.

About this medicine

OXERVATE ophthalmic solution contains cenegermin-bkbj, a recombinant form of human nerve growth factor produced in Escherichia coli.

Cenegermin-bkbj contains 118 amino acids. Cenegermin-bkbj has a relative molecular mass of 13,266 Daltons and the following molecular formula: C583H908N166O173S8. OXERVATE (cenegermin-bkbj) is a clear, colorless sterile solution with a pH of 7.0-7.4 and osmolarity 280-320 mOsm/kg for topical ophthalmic use.

Each mL contains Active: 20 mcg of cenegermin (0.002% w/v); Inactives: disodium hydrogen phosphate anhydrous (2.87 mg), hydroxypropylmethyl cellulose (1.0 mg), L-methionine (0.01 mg), mannitol (12.22 mg), polyethylene glycol 6000 (10.0 mg), sodium dihydrogen phosphate dihydrate (1.22 mg), trehalose dihydrate (47.03 mg), Water for Injection, USP, and hydrochloric acid and/or sodium hydroxide to adjust pH. OXERVATE does not contain an anti-microbial preservative. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 89e4bfec-d710-40ed-8885-5d13ba46b1cd. Read the full official label on DailyMed.

Related medicines

Azithromycin Latanoprost Amoxicillin and Clavulanate Cephalexin Sulfamethoxazole and Trimethoprim Ofloxacin Timolol Cefdinir